TrialBritish journal of haematology2015

Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.

Andre Goy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.